

1. Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II clinical trials. *Clin Cancer Res* 2009;15(6):1866-72.
2. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, et al. Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. *Clin Cancer Res* 2011;17(4):654-666.
3. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. *J Clin Oncol* 2012;30(23):2919-28.
4. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. *Clin Cancer Res* 2010;16(6):1745-55.
5. Dhani N, Tu D, Sargent DJ, Seymour L, Moore MJ. Alternate endpoints for screening phase II studies. *Clin Cancer Res* 2009;15(6):1873-82.
6. Forster MD, Saijo N, Seymour L, Calvert H. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan. *Clin Cancer Res* 2010;16(6):1737-44.
7. Hewitt SM, Badve SS, True LD. Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy. *Clin Cancer Res* 2012;18(6):1524-30.
8. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. *Clin Cancer Res* 2010;16(6):1726-36.
9. LaBarge MA. The difficulty of targeting cancer stem cell niches. *Clin Cancer Res* 2010;16(12):3121-9.
10. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. *Clin Cancer Res* 2010;16(6):1710-8.
11. Maitland ML. Cardiovascular toxicity of new agents. *Clin Adv Hematol Oncol* 2008;6(9):657-9.
12. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. *J Natl Cancer Inst* 2010;102(9):596-604.
13. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. *Clin Cancer Res* 2009;15(6):1898-905.

14. Merchant AA, Matsui W. Targeting Hedgehog--a cancer stem cell pathway. *Clin Cancer Res* 2010;16(12):3130-40.
15. Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM. Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031. *Clin Cancer Res* 2012;18(6):1547-54.
16. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. *Clin Cancer Res* 2010;16(12):3113-20.
17. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. *Clin Cancer Res* 2010;16(12):3141-52.
18. Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. *Clin Cancer Res* 2012;18(6):1515-23.
19. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Randomized phase II designs. *Clin Cancer Res* 2009;15(6):1883-90.
20. Sargent DJ, Taylor JM. Current issues in oncology drug development, with a focus on Phase II trials. *J Biopharm Stat* 2009;19(3):556-62.
21. Schilsky RL, Doroshow JH, Leblanc M, Conley BA. Development and use of integral assays in clinical trials. *Clin Cancer Res* 2012;18(6):1540-6.
22. Seymour L. Controversies in the Design of Phase II Clinical Trials. *Clinical Advances in Hematology & Oncology* 2010;8(2):95-97.
23. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. *Clin Cancer Res* 2010;16(6):1764-9.
24. Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. *Clin Cancer Res* 2009;15(6):1891-7.
25. Takebe N, Ivy SP. Controversies in cancer stem cells: targeting embryonic signaling pathways. *Clin Cancer Res* 2010;16(12):3106-12.
26. Weber JS, Atkins MB, Hwu P, Radvanyi L, Sznol M, Yee C. White Paper on Adoptive Cell Therapy for Cancer with Tumor Infiltrating Lymphocytes: a report of the CTEP Subcommittee on Adoptive Cell Therapy. *Clin Cancer Res* 2011.

IDSC Publications – December 13, 2012

27. Williams PM, Lively TG, Jessup JM, Conley BA. Bridging the gap: moving predictive and prognostic assays from research to clinical use. *Clin Cancer Res* 2012;18(6):1531-9.